异帕米星并头孢哌酮／舒巴坦治疗铜绿假单胞菌肺部感染的疗效

目的观察异帕米星联合头孢哌酮／舒巴坦治疗老年患者耐药铜绿假单胞菌肺部感染的临床疗效及安全性。方法将老年病房新发现的痰培养耐药铜绿假单胞菌阳性的患者随机分为异帕米星联合头孢哌N／舒巴坦治疗组（A组）和对照组（B组，单纯应用头孢哌酮／舒巴坦），观察两组的临床疗效、细菌清除率、血清肌酐值的变化。结果A组临床总有效率及细菌清除率明显高于B组，部分临床生化指标好转，未出现血清肌酐值明显上升的病例。结论异帕米星联合头孢哌酮／舒巴坦对耐药铜绿假单胞菌肺部感染临床疗效确定、安全性良好，是一个值得推广的临床抗菌药物。

Objective To observe the clinical therapy efficacy and safety of isepamicin combined with cefoperazone / sulbactam in pulmonary infection by drug-resistant pseudomonas aemginosa in elderly. Methods The old patients infected by drug-resistant pasedomonas aeruginosa isolated from sputum culture were randomly placed in either the isepamicin combined with cefoperazone/sulbactam group （ group A ） , or cefoperazone/sulbactam group （ group B ） . The clinical therapy efficacy, clean out rate of bacterium, and serum creatinine value were observed. Results The clinical therapy efficacy and clean out rate of bacterium in isepamicin combined with cefoperazone/sulbactam group were significantly better than that in cefoperazone /sulbactam group. The serum creatinine value was not increased significantly. Conclusion The clinical therapy pulmonary infection by drug-resistant pseudomonas aeruginosa with isepamicin combined with cefoperazone/sulbactam has better efficacy and security, and the clinical therapy strategy should be advocated.